• Home
  • Leadership
    • Management Team
    • Advisors
    • Scientific Advisory Board
    • Board of Directors
  • Therapeutic Programs
  • Media
  • Contact
GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors

GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors

by Damon Race | Apr 16, 2024 | In the News

Damon R. Race, President & CEO RALEIGH, N.C., April 16, 2024 /PRNewswire/ — GeneVentiv Therapeutics, developer of GENV-HEM (AAV8.FVa) for all hemophilias, announced today it has been awarded a Direct to Phase II Small Business Innovation Research (SBIR)...

Recent Posts

  • GeneVentiv Welcomes New Scientific Advisory Board Member, Sylvia Fong
  • GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors
  • New partners to develop universal gene therapy for hemophilia
  • ReciBioPharm and GeneVentiv Therapeutics partner to advance first AAV-based gene therapy for haemophilia patients with inhibitors
  • GeneVentiv to Attend BIO CEO & Investor Conference

Recent Comments

    Archives

    • July 2024
    • April 2024
    • March 2024
    • January 2024
    • November 2023
    • October 2023
    • September 2023
    • August 2023
    • May 2023
    • April 2023
    • February 2023
    • January 2023
    • September 2022
    • June 2022
    • March 2022
    • February 2022
    • November 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020

    Categories

    • In the News
    • Press

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact Us

    • Please prove you are human by selecting the Truck.
    • This field is for validation purposes and should be left unchanged.
    Copyright © 2024 GeneVentiv Therapeutics. All rights reserved.